JP2014503198A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503198A5
JP2014503198A5 JP2013541026A JP2013541026A JP2014503198A5 JP 2014503198 A5 JP2014503198 A5 JP 2014503198A5 JP 2013541026 A JP2013541026 A JP 2013541026A JP 2013541026 A JP2013541026 A JP 2013541026A JP 2014503198 A5 JP2014503198 A5 JP 2014503198A5
Authority
JP
Japan
Prior art keywords
bip
seq
heavy chain
human immunoglobulin
immunoglobulin heavy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013541026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503198A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/061862 external-priority patent/WO2012071422A2/en
Publication of JP2014503198A publication Critical patent/JP2014503198A/ja
Publication of JP2014503198A5 publication Critical patent/JP2014503198A5/ja
Withdrawn legal-status Critical Current

Links

JP2013541026A 2010-11-22 2011-11-22 組換え酵素および他のタンパク質のタンパク質発現および分泌を改善する新規シグナル配列 Withdrawn JP2014503198A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41592610P 2010-11-22 2010-11-22
US61/415,926 2010-11-22
PCT/US2011/061862 WO2012071422A2 (en) 2010-11-22 2011-11-22 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins

Publications (2)

Publication Number Publication Date
JP2014503198A JP2014503198A (ja) 2014-02-13
JP2014503198A5 true JP2014503198A5 (enExample) 2015-01-22

Family

ID=46146394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541026A Withdrawn JP2014503198A (ja) 2010-11-22 2011-11-22 組換え酵素および他のタンパク質のタンパク質発現および分泌を改善する新規シグナル配列

Country Status (19)

Country Link
US (1) US9279007B2 (enExample)
EP (2) EP3461905B1 (enExample)
JP (1) JP2014503198A (enExample)
KR (2) KR20190060888A (enExample)
CN (1) CN103328649B (enExample)
BR (1) BR112013012671B1 (enExample)
CA (1) CA2818689C (enExample)
CY (1) CY1121049T1 (enExample)
DK (2) DK3461905T3 (enExample)
ES (2) ES2687415T3 (enExample)
HR (1) HRP20181315T1 (enExample)
HU (1) HUE039070T2 (enExample)
LT (1) LT2643468T (enExample)
PL (1) PL2643468T3 (enExample)
PT (1) PT2643468T (enExample)
RS (1) RS57601B1 (enExample)
SI (1) SI2643468T1 (enExample)
SM (1) SMT201800466T1 (enExample)
WO (1) WO2012071422A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3164492T3 (pl) * 2014-07-03 2020-04-30 F. Hoffmann-La Roche Ag Układy ekspresji polipeptydu
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
KR102760654B1 (ko) 2017-06-07 2025-02-04 리제너론 파마슈티칼스 인코포레이티드 효소 내재화를 위한 조성물 및 방법
JP2021505135A (ja) * 2017-11-30 2021-02-18 アミカス セラピューティックス インコーポレイテッド Cdkl5発現変異体及びcdkl5融合タンパク質
MA51796A (fr) 2018-02-07 2020-12-16 Regeneron Pharma Procédés et compositions pour l'administration de protéines thérapeutiques
US10874750B2 (en) 2018-04-30 2020-12-29 Amicus Therapeutics, Inc. Gene therapy constructs and methods of use
US12252544B2 (en) 2018-05-17 2025-03-18 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020077114A2 (en) 2018-10-10 2020-04-16 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
JP2022514863A (ja) * 2018-12-19 2022-02-16 ヴェルサメブ アーゲー タンパク質をコードするrna
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
CN114072515A (zh) * 2019-04-30 2022-02-18 宾夕法尼亚州大学信托人 可用于治疗庞贝病的组合物
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス, インコーポレイテッド Ca2の組成物および調整可能な制御方法
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN112342247B (zh) * 2020-11-10 2022-03-11 江苏科技大学 一种提高家蚕细胞表达外源蛋白分泌率的方法
MX2023006445A (es) 2020-12-01 2023-08-10 Univ Pennsylvania Composiciones y usos de estas para el tratamiento del síndrome de angelman.
WO2023086939A1 (en) 2021-11-12 2023-05-19 Amicus Therapeutics, Inc. Compositions and methods for treating mucopolysaccharidosis iiia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4892132B2 (ja) * 1998-11-24 2012-03-07 ブリストル−マイヤーズ スクイブ カンパニー 70kD熱ショック蛋白による化合物の細胞内標的輸送
WO2005047302A1 (en) * 2003-11-06 2005-05-26 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
WO2007115724A2 (en) * 2006-04-11 2007-10-18 Csl Behring Gmbh Method of increasing the in vivo recovery of therapeutic polypeptides

Similar Documents

Publication Publication Date Title
JP2014503198A5 (enExample)
WO2012071422A3 (en) Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
CN105765063B (zh) 应用改变的辅助噬菌体制备抗原结合分子的方法
JP2005120106A5 (enExample)
JP2003524587A5 (enExample)
JP2019521643A5 (enExample)
DK2190863T3 (en) New albumin binding compositions, methods and uses
JP2016505251A5 (enExample)
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
CY1112334T1 (el) Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων
Gallizia et al. Production of a soluble and functional recombinant streptavidin inescherichia coli
JP2015212284A5 (enExample)
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
CA2636075A1 (en) Chimaeric fusion protein with superior chaperone and folding activities
JP2016508143A5 (enExample)
JP2021500035A5 (enExample)
RU2016105586A (ru) Гибридная конструкция, включающая антигенсвязывающий фрагмент, специфичный к сывороточному альбумину и эффекторный компонент, и способы ее получения
JP2008509682A5 (enExample)
JP2017526625A5 (enExample)
CN106868025B (zh) 用酵母制备三聚体埃博拉病毒糖蛋白突变体的方法
JP6199054B2 (ja) 抗イヌIgEモノクローナル抗体並びに抗イヌIgEモノクローナル抗体の重鎖可変領域及び軽鎖可変領域
CN102617734B (zh) 抗FGF-2抗体Dab-2及其应用
CN118496349A (zh) 抗猴痘病毒a35r蛋白的单克隆抗体2d7或其抗体片段
CN110903402A (zh) 一种双特异性融合蛋白及其构建方法与应用
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof